440 related articles for article (PubMed ID: 35852527)
21. Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial.
Solomon SD; Claggett BL; Miao ZM; Diaz R; Felker GM; McMurray JJV; Metra M; Corbalan R; Filippatos G; Goudev AR; Mareev V; Serpytis P; Suter T; Yilmaz MB; Zannad F; Kupfer S; Heitner SB; Malik FI; Teerlink JR
Eur Heart J; 2022 Jun; 43(23):2212-2220. PubMed ID: 35325102
[TBL] [Abstract][Full Text] [Related]
22. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.
Edelmann F; Wachter R; Schmidt AG; Kraigher-Krainer E; Colantonio C; Kamke W; Duvinage A; Stahrenberg R; Durstewitz K; Löffler M; Düngen HD; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Gelbrich G; Pieske B;
JAMA; 2013 Feb; 309(8):781-91. PubMed ID: 23443441
[TBL] [Abstract][Full Text] [Related]
23. Tricuspid Regurgitation and Clinical Outcomes in Heart Failure With Reduced Ejection Fraction.
Adamo M; Metra M; Claggett BL; Miao ZM; Diaz R; Felker GM; McMurray JJV; Solomon SD; Biering-Sørensen T; Divanji PH; Heitner SB; Kupfer S; Malik FI; Teerlink JR;
JACC Heart Fail; 2024 Mar; 12(3):552-563. PubMed ID: 38300212
[TBL] [Abstract][Full Text] [Related]
24. Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF Trial.
Pabon M; Cunningham J; Claggett B; Felker GM; McMurray JJV; Metra M; Diaz R; Wang X; Arias-Mendoza A; Bonderman D; Crespo-Leiro M; Fonseca C; Goncalvesova E; Lund M; O'Meara E; Sliwa-Hahnle K; Malik FI; Solomon SD; Teerlink JR;
JACC Heart Fail; 2023 Dec; 11(12):1729-1738. PubMed ID: 37831045
[TBL] [Abstract][Full Text] [Related]
25. Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial.
Borlaug BA; Anstrom KJ; Lewis GD; Shah SJ; Levine JA; Koepp GA; Givertz MM; Felker GM; LeWinter MM; Mann DL; Margulies KB; Smith AL; Tang WHW; Whellan DJ; Chen HH; Davila-Roman VG; McNulty S; Desvigne-Nickens P; Hernandez AF; Braunwald E; Redfield MM;
JAMA; 2018 Nov; 320(17):1764-1773. PubMed ID: 30398602
[TBL] [Abstract][Full Text] [Related]
26. Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF.
Lanfear DE; Njoroge JN; Adams KF; Anand I; Fang JC; Ramires F; Sliwa-Hahnle K; Badat A; Burgess L; Gorodeski EZ; Williams C; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon S; Miao ZM; Claggett BL; Heitner SB; Kupfer S; Malik FI; Teerlink JR
JACC Heart Fail; 2023 May; 11(5):569-579. PubMed ID: 36881396
[TBL] [Abstract][Full Text] [Related]
27. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
[TBL] [Abstract][Full Text] [Related]
28. Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity.
Bakkehaug JP; Kildal AB; Engstad ET; Boardman N; Næsheim T; Rønning L; Aasum E; Larsen TS; Myrmel T; How OJ
Circ Heart Fail; 2015 Jul; 8(4):766-75. PubMed ID: 26025342
[TBL] [Abstract][Full Text] [Related]
29. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.
Armstrong PW; Lam CSP; Anstrom KJ; Ezekowitz J; Hernandez AF; O'Connor CM; Pieske B; Ponikowski P; Shah SJ; Solomon SD; Voors AA; She L; Vlajnic V; Carvalho F; Bamber L; Blaustein RO; Roessig L; Butler J;
JAMA; 2020 Oct; 324(15):1512-1521. PubMed ID: 33079152
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of omecamtiv mecarbil for heart failure: A systematic review and meta-analysis.
Alqatati F; Elbahnasawy M; Bugazia S; Ragab KM; Elsnhory AB; Shehata M; Elsayed SM; Fathy MA; Nourelden AZ
Indian Heart J; 2022; 74(3):155-162. PubMed ID: 35301008
[TBL] [Abstract][Full Text] [Related]
31. Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial.
Metra M; Pagnesi M; Claggett BL; Díaz R; Felker GM; McMurray JJV; Solomon SD; Bonderman D; Fang JC; Fonseca C; Goncalvesova E; Howlett JG; Li J; O'Meara E; Miao ZM; Abbasi SA; Heitner SB; Kupfer S; Malik FI; Teerlink JR
Eur Heart J; 2022 Dec; 43(48):5006-5016. PubMed ID: 35675469
[TBL] [Abstract][Full Text] [Related]
32. Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
Omar M; Jensen J; Ali M; Frederiksen PH; Kistorp C; Videbæk L; Poulsen MK; Tuxen CD; Möller S; Gustafsson F; Køber L; Schou M; Møller JE
JAMA Cardiol; 2021 Jul; 6(7):836-840. PubMed ID: 33404637
[TBL] [Abstract][Full Text] [Related]
33. Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial.
Docherty KF; Jhund PS; Claggett B; Ferreira JP; Bengtsson O; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; McMurray JJV;
JAMA Cardiol; 2021 Nov; 6(11):1298-1305. PubMed ID: 34319398
[TBL] [Abstract][Full Text] [Related]
34. Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina.
Greenberg BH; Chou W; Saikali KG; Escandón R; Lee JH; Chen MM; Treshkur T; Megreladze I; Wasserman SM; Eisenberg P; Malik FI; Wolff AA; Shaburishvili T
JACC Heart Fail; 2015 Jan; 3(1):22-29. PubMed ID: 25453536
[TBL] [Abstract][Full Text] [Related]
35. Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil.
Kaplinsky E; Mallarkey G
Drugs Context; 2018; 7():212518. PubMed ID: 29707029
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure.
Vu T; Ma P; Xiao JJ; Wang YM; Malik FI; Chow AT
J Clin Pharmacol; 2015 Nov; 55(11):1236-47. PubMed ID: 25951506
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis.
Pagnesi M; Baldetti L; Aimo A; Inciardi RM; Tomasoni D; Vizzardi E; Vergaro G; Emdin M; Lombardi CM
J Clin Med; 2022 Jan; 11(2):. PubMed ID: 35054042
[TBL] [Abstract][Full Text] [Related]
38. Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction.
Psotka MA; Teerlink JR
Handb Exp Pharmacol; 2017; 243():465-490. PubMed ID: 28315072
[TBL] [Abstract][Full Text] [Related]
39. Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.
Hundertmark MJ; Adler A; Antoniades C; Coleman R; Griffin JL; Holman RR; Lamlum H; Lee J; Massey D; Miller JJJJ; Milton JE; Monga S; Mózes FE; Nazeer A; Raman B; Rider O; Rodgers CT; Valkovič L; Wicks E; Mahmod M; Neubauer S
Circulation; 2023 May; 147(22):1654-1669. PubMed ID: 37070436
[TBL] [Abstract][Full Text] [Related]
40. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency.
van Veldhuisen DJ; Ponikowski P; van der Meer P; Metra M; Böhm M; Doletsky A; Voors AA; Macdougall IC; Anker SD; Roubert B; Zakin L; Cohen-Solal A;
Circulation; 2017 Oct; 136(15):1374-1383. PubMed ID: 28701470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]